Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLUGLIO: Glutamate Inhibitors with Chemoradiotherapy for Glioblastoma
NCT05664464Phase 2Recruiting
- Sponsor
- University of Zurich
- Start
- Jan 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gabapentin, 5-aminosalicylic acid + sulphasalazine, memantine in glioblastoma (GBM), sponsored by University of Zurich. Started Jan 2023; status: recruiting.
02
Drugs
gabapentin5-aminosalicylic acid + sulphasalazinememantine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05664464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664464.